F/M Emerald Life Sciences Innovation ETF (LFSC)

Assets	$120.65M
Expense Ratio	0.54%
PE Ratio	n/a
Shares Out	2.78M
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a

Volume	2,399
Open	43.78
Previous Close	43.46
Day's Range	43.20 - 43.93
52-Week Low	29.31
52-Week High	48.78
Beta	0.94
Holdings	42
Inception Date	Oct 31, 2024

About LFSC

Fund Home Page

The F/M Emerald Life Sciences Innovation ETF (LFSC) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed ETF that targets US health care and biotechnology companies identified to have promising life sciences opportunities. LFSC was launched on Oct 31, 2024 and is issued by F/m Investments.

• Asset Class: Equity
• Category: Health
• Region: North America
• Stock Exchange: Nasdaq
• Ticker Symbol: LFSC
• ETF Provider: F/m Investments

Top 10 Holdings

52.53% of assets

Name	Symbol	Weight
Corcept Therapeutics Incorporated	CORT	7.13%
Travere Therapeutics, Inc.	TVTX	6.61%
LivaNova PLC	LIVN	6.52%
Cogent Biosciences, Inc.	COGT	6.17%
Spyre Therapeutics, Inc.	SYRE	5.33%
BillionToOne, Inc.	BLLN	4.74%
Replimune Group, Inc.	REPL	4.55%
Guardant Health, Inc.	GH	4.42%
Veradermics, Incorporated	MANE	3.60%
Axsome Therapeutics, Inc.	AXSM	3.46%

Performance

LFSC had a total return of 47.11% in the past year, including dividends. Since the fund's inception, the average annual return has been 33.24%.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP. Several fund data points are also provided by Finnhub.

Last checked:

Oct 3, 2026

Data Sources Report a data error